A5102887304- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Helicobacter pylori-related gastroenterology studies
- Urinary and Genital Oncology Studies
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Gastric Cancer Management and Outcomes
- Gastroesophageal reflux and treatments
- Biomedical Ethics and Regulation
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Eosinophilic Esophagitis
- Economic and Financial Impacts of Cancer
- Microscopic Colitis
- Pharmaceutical Economics and Policy
- Gastrointestinal disorders and treatments
- Veterinary medicine and infectious diseases
- Cervical Cancer and HPV Research
- Lung Cancer Treatments and Mutations
- Esophageal and GI Pathology
Cytel (United States)
2021-2024
Helicobacter pylori (Hp) is causal in benign and malignant gastrointestinal diseases. Accordingly, current guidelines recommend Hp eradication patients with active infection. Unfortunately, treatment failure common, exposing to complications associated persistent infection consequences of repeated treatment, including promotion antibiotic resistance. In the United States (US), data regarding rates available therapies are limited. Moreover, clinical economic burden have not been thoroughly...
Erosive esophagitis (EE) occurs when refluxate from the stomach causes T-lymphocyte infiltration of esophageal mucosa, resulting in mucosal breaks. Currently, therapy with proton-pump inhibitors (PPIs) is standard treatment for EE United States, but few comprehensive reviews exist on efficacy PPIs US populations. Here, we present most contemporary, thorough analysis PPI rates, and identify characterize patient subgroups at risk poor healing outcomes.We searched literature to studies...
Helicobacter pylori eradication rates achieved with clarithromycin-based triple therapies are declining due to antibiotic resistance, but data regarding temporal changes in efficacy these scarce. To evaluate the of regimens over time. A comprehensive literature review and time-trend analysis. Bibliographies recently published systematic reviews were searched supplemented a targeted conducted using Medline Embase databases ProQuest from conception May 2021. Studies reporting H. included...
589 Background: Gemcitabine + cisplatin (GC) is one of the most effective and commonly used regimens in la/mUC. In GC, dosed at 70 mg/m 2 on day 1 a 3-week cycle; however, for many pts, impaired renal or cardiac function, neuropathy, poor performance status can preclude use cisplatin. A promising alternative split-dose where dose divided over days. We conducted an SLR NMA to better understand outcomes, toxicity, comparative effectiveness GC vs GCarboplatin (GCa), methotrexate vinblastine...